Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
What neoadjuvant regimen would use you for a patient over 70 years old with resectable gastric cancer?
Related Questions
Would you consider using enasidenib off-label for a cholangiocarcinoma with IDH2 mutation that has progressed on numerous lines of standard of therapy?
When treating with SBRT and immunotherapy for unresectable HCC, how do you sequence the treatment?
Would you rechallenge with cabozantinib in a patient with HCC after the development of a 6 mm gastrohepatic fistula without perforation or communication with the peritoneal cavity?
How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?
If using GCSF with mFOLFIRINOX, would you ever use it during day 1?
What would your approach be for a locally advanced head and neck cancer diagnosed concurrently with a mid-esophageal cancer?
What is the recommended dose of aspirin for prevention of colon polyp?
What systemic therapy would you use in patients with gastric cancer who had a relapse after Durva-FLOT (MATTERHORN regimen)?
How do you differentiate between ERBB2 mutation vs HER2 overexpression testing when selecting patients for tumor-agnostic therapy?
How do CheckMate 8HW results impact your sequencing of available therapies in dMMR/MSI-H metastatic colorectal cancer?
